Journal of Acute Care

Register      Login

VOLUME 1 , ISSUE 2 ( May-August, 2022 ) > List of Articles

PICTORIAL ESSAY

Pyoderma Gangrenosum in an Immunosuppressed Patient

Sudhakar Almad

Keywords : Azathioprine, Inflammatory exudate, Immunosuppression, Neutrophil dysfunction, Pyoderma gangrenosum

Citation Information : Almad S. Pyoderma Gangrenosum in an Immunosuppressed Patient. 2022; 1 (2):110-111.

DOI: 10.5005/jp-journals-10089-0018

License: CC BY-NC 4.0

Published Online: 31-12-2022

Copyright Statement:  Copyright © 2022; The Author(s).


Abstract

Pyoderma gangrenosum (PG) is a rare, cutaneous, and ulcerative disorder that occurs as a result of neutrophil dysfunction and is generally seen in patients with underlying systemic diseases. PG is mainly treated by corticosteroids and immunosuppressive agents. We present this case as a rare case of rapidly progressive PG in a lady with sarcoidosis that occurred despite being on immunosuppression with azathioprine.


HTML PDF Share
  1. Bhat RM. Pyoderma gangrenosum: an update. Indian Dermatol Online J 2012;3(1):7–13. DOI: 10.4103/2229-5178.93482
  2. von den Driesch P. Pyoderma gangrenosum: a report of 44 cases with follow-up. Br J Dermatol 2008;137(6):1000–1005. DOI: 10.1046/j.1365-2133.1997.20022083.x
  3. Adachi Y, Kindzelskii AL, Cookingham G, et al. Aberrant neutrophil trafficking and metabolic oscillations in severe pyoderma gangrenosum. J Invest Dermatol 1998;111(2):259–268. DOI: 10.1046/j.1523-1747.1998.00311.x
  4. Farasat S, Aksentijevich I, Toro JR. Autoinflammatory diseases: clinical and genetic advances. Arch Dermatol 2008;144(3):392–402. DOI: 10.1001/archderm.144.3.392
  5. Ahronowitz I, Harp J, Shinkai K. Etiology and management of pyoderma gangrenosum: a comprehensive review. Am J Clin Dermatol 2012;13(3):191–211. DOI: 10.2165/11595240-000000000-00000
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.